Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, ...

Fintel reports that on July 23, 2025, BMO Capital downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Underperform. Analyst Price Forecast Suggests 595.73% Upside As of ...

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from ...

View the latest Replimune Group Inc. (REPL) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Replimune Group (NASDAQ:REPL – Get Free Report) ‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports ...

Replimune Group granted stock options and restricted shares to ten new non-executive employees as part of their incentive plan.

On Monday, Piper Sandler analysts increased their price target for Replimune Group stock to $22 from $14, while maintaining an Overweight rating. The adjustment follows several recent updates from the ...

Replimune Group Inc. (REPL) reported its first-quarter earnings for 2025, revealing a significant miss on expected earnings per share (EPS) and a subsequent drop in stock price. The company posted an ...

REPLIMUNE GROUP Hedge Fund Activity We have seen 83 institutional investors add shares of REPLIMUNE GROUP stock to their portfolio, and 81 decrease their positions in their most recent quarter.